Editorial Board Member Collection Series: “Image-Guided Interventions in Cancer: From Biopsies to Therapies”

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 2092

Special Issue Editors


E-Mail Website
Guest Editor
Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
Interests: molecular imaging; image guided therapy; image guided surgery; surgical navigation; robotic surgery; minimally invasive surgery; local therapy; theranostics; chemistry; engineering

E-Mail Website
Guest Editor
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Interests: external beam radiation therapy; image-guided radiation therapy; photodynamic therapy; small field dosimetry; monitor unit calculations; testicular self-examination; total body irradiation; in-vivo radiation dosimetry

Special Issue Information

Dear Colleagues,

The continuously increasing accuracy that can be achieved by clinical diagnostic disciplines such as radiology, nuclear medicine, and pathology is increasing due to the emergence of new applications of biomedical optics. This evolution has set the stage to extend the role that imaging plays in patient management. For example, modern imaging has the potential to guide (therapeutic) interventions and to help guide precision therapy. These interventions can be performed by the medical disciplines of, e.g., interventional radiology and nuclear medicine as well as surgery and radiotherapy. In addition to being guided by more traditional radiological and nuclear medicine modalities, there has been a rapid rise in the interventional use of magnetic and optical approaches, the latter including fluorescence-guided surgery and photodynamic therapy. Given the plurality of the diagnostic imaging techniques available for initial staging, each clinical challenge can be met with a tailored image guidance solution. The type of primary cancer or (nodal) metastases lesions being targeted may also substantially influence the choice of imaging guidance strategy. In general, however, in clinic pre-operative imaging, e.g., MRI, CT, PET/CT, and diffuse optical, imaging acts as a roadmap that treating physicians can use to navigate towards the target, representing a process that can be facilitated by “gps-like” navigation platforms. During the intervention itself, secondary modalities, e.g., (cone-beam) CT, US, radio, or optical guidance, are used to zoom in on the target and to assure that accurate treatment is delivered. In all cases, the fluent connection of pre-intervention and interventional imaging strategies poses specific technical challenges that demand the development of new imaging technologies. To make sure imaging strategies are accepted in routine clinical care, evidence that underscores how and to what extent image guidance creates a positive impact needs to be collected.

This Special Issue aims to provide an up-to-date overview of the most recent (technical) advances in the field of image-guided oncological interventions. For a variety of cancers and interventions, we will cover the in vivo use of innovative image guidance technologies for a wide range of modalities. Translational efforts and work that demonstrate the benefits for patients and/or treating physicians is of particular interest.

Prof. Dr. Fijs W.B. Van Leeuwen
Prof. Dr. Timothy C. Zhu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional radiology

  • interventional nuclear medicine
  • image guided therapy
  • image guided surgery
  • molecular imaging
  • local treatment
  • surgical navigation
  • Photodynamic therapy
  • Biomedical photonics
  • Diffuse optical imaging

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 6211 KiB  
Article
Fractionated Photofrin-Mediated Photodynamic Therapy Significantly Improves Long-Term Survival
by Hongjing Sun, Weibing Yang, Yihong Ong, Theresa M. Busch and Timothy C. Zhu
Cancers 2023, 15(23), 5682; https://doi.org/10.3390/cancers15235682 - 01 Dec 2023
Viewed by 755
Abstract
This study investigates the effect of fractionated (two-part) PDT on the long-term local control rate (LCR) using the concentration of reactive oxygen species ([ROS]rx) as a dosimetry quantity. Groups with different fractionation schemes are examined, including a 2 h interval between [...] Read more.
This study investigates the effect of fractionated (two-part) PDT on the long-term local control rate (LCR) using the concentration of reactive oxygen species ([ROS]rx) as a dosimetry quantity. Groups with different fractionation schemes are examined, including a 2 h interval between light delivery sessions to cumulative fluences of 135, 180, and 225 J/cm2. While the total treatment time remains constant within each group, the division of treatment time between the first and second fractionations are explored to assess the impact on long-term survival at 90 days. In all preclinical studies, Photofrin is intravenously administered to mice at a concentration of 5 mg/kg, with an incubation period between 18 and 24 h before the first light delivery session. Fluence rate is fixed at 75 mW/cm2. Treatment ensues via a collimated laser beam, 1 cm in diameter, emitting light at 630 nm. Dosimetric quantities are assessed for all groups along with long-term (90 days) treatment outcomes. This study demonstrated a significant improvement in long-term survival after fractionated treatment schemes compared to single-fraction treatment, with the optimal 90-day survival increasing to 63%, 86%, and 100% vs. 20%, 25%, and 50%, respectively, for the three cumulative fluences. The threshold [ROS]rx for the optimal scheme of fractionated Photofrin-mediated PDT, set at 0.78 mM, is significantly lower than that for the single-fraction PDT, at 1.08 mM. Full article
Show Figures

Figure 1

14 pages, 1590 KiB  
Article
EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
by Fabian Falkenbach, Francesca Ambrosini, Pierre Tennstedt, Matthias Eiber, Matthias M. Heck, Felix Preisser, Markus Graefen, Lars Budäus, Daniel Koehler, Sophie Knipper and Tobias Maurer
Cancers 2023, 15(20), 5008; https://doi.org/10.3390/cancers15205008 - 16 Oct 2023
Cited by 1 | Viewed by 910
Abstract
Objective: To assess the influence of biochemical recurrence (BCR) risk groups and PSA kinetics on the outcomes of radioguided surgery against prostate-specific membrane antigen (PSMA-RGS). Currently, neither BCR risk group nor PSA doubling time (PSA-DT), or PSA velocity (PSA-V) are actively assigned or [...] Read more.
Objective: To assess the influence of biochemical recurrence (BCR) risk groups and PSA kinetics on the outcomes of radioguided surgery against prostate-specific membrane antigen (PSMA-RGS). Currently, neither BCR risk group nor PSA doubling time (PSA-DT), or PSA velocity (PSA-V) are actively assigned or relevant for counseling prior to PSMA-RGS. Methods: We retrospectively analyzed PSMA-RGS cases for oligorecurrent prostate cancer between 2014 and 2023. BCR risk groups, PSA-DT, and PSA-V were analyzed as predictors for complete biochemical response (cBR, PSA < 0.2 ng/mL), BCR-free, and therapy-free survival (BCRFS, TFS). Results: Of 374 included patients, only 21/374 (6%) and 201/374 (54%) were classified as low- and high-risk BCR (no group assignment possible in 152/374, 41%). A total of 13/21 (62%) patients with low- and 120/201 (60%) with high-risk BCR achieved cBR (p = 1.0). BCR classification was no predictor for BCRFS (HR:1.61, CI: 0.70–3.71, p = 0.3) or subsequent TFS (HR:1.07, CI: 0.46–2.47, p = 0.9). A total of 47/76 (62%) patients with PSA-DT ≤ 6 mo and 50/84 (60%) with PSA-DT > 6 mo achieved cBR (p = 0.4). PSA-DT was not associated with cBR (OR: 0.99, CI: 0.95–1.03, p = 0.5), BCRFS (HR: 1.00, CI: 0.97–1.03, p = 0.9), or TFS (HR: 1.02, CI: 0.99–1.04, p = 0.2). Consistent negative findings were recorded for PSA-V. Conclusions: The BCR risk groups and PSA kinetics do not predict the oncological success of PSMA-RGS performed at low absolute PSA values. Indolent low-risk BCR is rarely treated by PSMA-RGS. Full article
Show Figures

Figure 1

Back to TopTop